Working… Menu

Neuromodulation for Hypothalamic Obesity

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03708913
Recruitment Status : Withdrawn (no participants have been able to qualify for study)
First Posted : October 17, 2018
Last Update Posted : November 2, 2020
Information provided by (Responsible Party):
Christopher Honey, University of British Columbia

Brief Summary:
The balance between hunger and satiety is imperative for an individual's survival and overall health.). Without this balance, individuals can become morbidly obese or lack adequate nutrition for survival. Craniopharyngioma (CP) is a benign tumour that occurs at the base of the brain in children. Unfortunately, pediatric neurosurgeons sometimes inadvertently destroy a child's satiety centre during CP tumour removal surgery. This leaves the child with a post-operative complication: an insatiable appetite. This form of obesity is called "hypothalamic obesity". This study is designed to investigate Deep Brain Stimulation for hypothalamic obesity in n=6 young adults who have stabilized tumours.

Condition or disease Intervention/treatment Phase
Craniopharyngioma Hypothalamic Obesity Metabolic Syndrome Device: Hypothalamic Deep Brain Stimulation Not Applicable

Detailed Description:
For young adults with destroyed satiety centres due to childhood CP surgery, we believe directly re-balancing the brain's control of hunger and satiety is necessary for sustained and long-term therapy. n=6 patients will be recruited in this Phase 1 DBS trial. The proposed research will hope to improve personal health among the young adults involved in this study by improving quality of life and avoiding long-term cardiovascular morbidities. Furthermore, this study will elucidate what brain regions drive excessive hunger and develop a treatment that attempts to reverse these abnormalities.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Deep Brain Stimulation for Hypothalamic Obesity: A Surgical & Neuroimaging Study
Actual Study Start Date : June 1, 2019
Actual Primary Completion Date : December 1, 2019
Actual Study Completion Date : April 1, 2020

Arm Intervention/treatment
Experimental: Open-Label Lateral Hypothalamic DBS Stimulation
Open-label lateral hypothalamic DBS stimulation for 1 year.
Device: Hypothalamic Deep Brain Stimulation
One-year continuous hypothalamic deep brain stimulation

Primary Outcome Measures :
  1. Number of Participants With Adverse Events That Are Related to surgery and Post-Operative Side Effects [ Time Frame: 12 months ]

Secondary Outcome Measures :
  1. Body Mass Index (BMI) [ Time Frame: 12 months ]
    Measuring BMI(kg/m^2) following 12 months of constant stimulation

  2. Hyperphagia Questionnaire [ Time Frame: 12 months ]
    Completion of hyperphagia questionnaire

  3. SF-36 Quality of Life Questionnaire [ Time Frame: 12 months ]
    Completion of QoL Questionnaire

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 30 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosed with hypothalamic obesity following craniopharyngioma tumour removal
  • Treatment refractory to pharmacological interventions such as growth hormone therapy and anti-obesity medications

Exclusion Criteria:

  • Unable to give consent or unmanaged psychiatric condition

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03708913

Layout table for location information
Canada, British Columbia
Leslie and Gordon Diamond Health Center
Vancouver, British Columbia, Canada, V5Z1M9
Sponsors and Collaborators
University of British Columbia
Layout table for additonal information
Responsible Party: Christopher Honey, Professor & Neurosurgeon, University of British Columbia Identifier: NCT03708913    
Other Study ID Numbers: H16-01595
First Posted: October 17, 2018    Key Record Dates
Last Update Posted: November 2, 2020
Last Verified: October 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Metabolic Syndrome
Nutrition Disorders
Body Weight
Insulin Resistance
Glucose Metabolism Disorders
Metabolic Diseases
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Bone Neoplasms
Neoplasms by Site
Bone Diseases
Musculoskeletal Diseases